Genome-Based Therapeutics

Genome-Based Therapeutics

AA.VV

32,76 €
IVA incluido
Disponible
Editorial:
National Academies Press
Año de edición:
2012
Materia
Servicios de primeros auxilios y de auxiliares sanitarios
ISBN:
9780309260244
32,76 €
IVA incluido
Disponible

Selecciona una librería:

  • Librería Samer Atenea
  • Librería Aciertas (Toledo)
  • Kálamo Books
  • Librería Perelló (Valencia)
  • Librería Elías (Asturias)
  • Donde los libros
  • Librería Kolima (Madrid)
  • Librería Proteo (Málaga)

The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process.Genome-Based Therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients’ reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two.Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New Paradigms in Drug Discovery: How Genomic Data Are Being Used to Revolutionize the Drug Discovery and Development Process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead.

Artículos relacionados

  • Primeros auxilios. MF0272.
    Olga Martín Villaoslada
    Puede solicitar gratuitamente las soluciones a todas las actividades en el email tutor@tutorformacion.esCapacidades que se adquieren con este Manual:- Identificar las características de la asistencia como primer interviniente.- Aplicar técnicas de valoración inicial según el protocolo establecido accediendo al accidentado de forma oportuna y generando un entorno seguro.- Aplica...
    Disponible

    22,83 €

  • Direct-to-Consumer Genetic Testing
    Today, scores of companies, primarily in the United States and Europe, are offering whole genome scanning services directly to the public. The proliferation of these companies and the services they offer demonstrate a public appetite for this information and where the future of genetics may be headed; they also demonstrate the need for serious discussion about the regulatory en...
    Disponible

    35,31 €

  • Incorporating Occupational Information in Electronic Health Records
    Each year in the United States, more than 4,000 occupational fatalities and more than 3 million occupational injuries occur along with more than 160,000 cases of occupational illnesses. Incorporating patients’ occupational information into electronic health records (EHRs) could lead to more informed clinical diagnosis and treatment plans as well as more effective policies, inte...
    Disponible

    31,72 €

  • Cognitive Rehabilitation Therapy for Traumatic Brain Injury
    Traumatic brain injury (TBI) may affect 10 million people worldwide. It is considered the ’signature wound’ of the conflicts in Iraq and Afghanistan. These injuries result from a bump or blow to the head, or from external forces that cause the brain to move within the head, such as whiplash or exposure to blasts. TBI can cause an array of physical and mental health concerns and...
    Disponible

    58,19 €

  • Health IT and Patient Safety
    IOM’s 1999 landmark study To Err is Human estimated that between 44,000 and 98,000 lives are lost every year due to medical errors. This call to action has led to a number of efforts to reduce errors and provide safe and effective health care. Information technology (IT) has been identified as a way to enhance the safety and effectiveness of care. In an effort to catalyze its i...
    Disponible

    43,63 €

  • A Research Strategy for Environmental, Health, and Safety Aspects of Engineered Nanomaterials
    The nanotechnology sector, which generated about $225 billion in product sales in 2009, is predicted to expand rapidly over the next decade with the development of new technologies that have new capabilities. The increasing production and use of engineered nanomaterials (ENMs) may lead to greater exposures of workers, consumers, and the environment, and the unique scale-specifi...
    Disponible

    51,48 €